Joseph Catanzaro
Stock Analyst at Mizuho
(3.38)
# 987
Out of 5,055 analysts
97
Total ratings
45%
Success rate
5.57%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Initiates: Outperform | $24 | $12.80 | +87.50% | 3 | Oct 21, 2025 | |
| RVMD Revolution Medicines | Initiates: Outperform | $90 | $67.75 | +32.84% | 3 | Oct 21, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Outperform | $48 | $25.55 | +87.87% | 1 | Oct 21, 2025 | |
| APGE Apogee Therapeutics | Initiates: Outperform | $105 | $65.50 | +60.31% | 1 | Oct 21, 2025 | |
| KYMR Kymera Therapeutics | Initiates: Outperform | $81 | $64.94 | +24.73% | 1 | Oct 21, 2025 | |
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.08 | +140.38% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $3.88 | +28.87% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $2.47 | +142.91% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $17.64 | +155.10% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $96.01 | -12.51% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $125.02 | -12.01% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $41.65 | -8.76% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $17.26 | -13.07% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $70.03 | -24.32% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $2.13 | +369.48% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.28 | +1,384.38% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $10.20 | +86.27% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $4.01 | +274.06% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $25.60 | +40.63% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $8.80 | +354.55% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $11.30 | +32.74% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $1.16 | +287.93% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $2.24 | +1,239.29% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.25 | +1,500.00% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $8.17 | +120.32% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.65 | +1,415.15% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $6.20 | -71.77% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $23.18 | -13.72% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.12 | -29.25% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $8.01 | +2,398.44% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $9.24 | +278.79% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.92 | +6,400.54% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.64 | +581.82% | 3 | Apr 7, 2020 |
Nurix Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $24
Current: $12.80
Upside: +87.50%
Revolution Medicines
Oct 21, 2025
Initiates: Outperform
Price Target: $90
Current: $67.75
Upside: +32.84%
Celldex Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $25.55
Upside: +87.87%
Apogee Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $105
Current: $65.50
Upside: +60.31%
Kymera Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $81
Current: $64.94
Upside: +24.73%
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.08
Upside: +140.38%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $3.88
Upside: +28.87%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.47
Upside: +142.91%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $17.64
Upside: +155.10%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $96.01
Upside: -12.51%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $125.02
Upside: -12.01%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $41.65
Upside: -8.76%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $17.26
Upside: -13.07%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $70.03
Upside: -24.32%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.13
Upside: +369.48%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.28
Upside: +1,384.38%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $10.20
Upside: +86.27%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $4.01
Upside: +274.06%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $25.60
Upside: +40.63%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $8.80
Upside: +354.55%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $11.30
Upside: +32.74%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $1.16
Upside: +287.93%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $2.24
Upside: +1,239.29%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.25
Upside: +1,500.00%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $8.17
Upside: +120.32%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.65
Upside: +1,415.15%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $6.20
Upside: -71.77%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $23.18
Upside: -13.72%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.12
Upside: -29.25%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $8.01
Upside: +2,398.44%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $9.24
Upside: +278.79%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $0.92
Upside: +6,400.54%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.64
Upside: +581.82%